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ABSTRACT:
Introduction: Spinal anesthesia is considered a reasonable option for cesarean section. Bupivacaine and ropivacaine 
have been used as intrathecal drugs alone or in combination with various opioids. Ropivacaine is considered a valid 
and safe alternative to bupivacaine for intrathecal anesthesia. This study aims to determine the median effective 
dose (ED50) of intrathecal bupivacaine and ropivacaine for cesarean section and defines this as the minimum local 
anesthetic dose (MLAD). Methods: Forty pregnant women undergoing elective cesarean section were allocated and 
randomized into two groups. The initial dose was 13mg for both ropivacaine and bupivacaine groups and was increased 
or decreased of 0.3mg, using the up-down sequential allocation technique. Efficacy was accepted if adequate sensory 
dermatomal anesthesia to pinprick to T6 was attained within 20 minutes after intrathecal injection and required no 
supplemental epidural injection for procedure until at least 50 minutes after the intrathecal injection of test drugs. The 
MLAD for both bupivacaine and ropivacaine was calculated with 95% confidence interval using the formula of Dixon 
and Massey. Comparison of different variables between the groups was done using t-test with significant p value at 
< 0.05. Results: The two groups were comparable in terms of demographic profile and clinical characteristics. The 
MLAD of ropivacaine and bupivacaine were 11.63 mg (95% CI, 11.5-12.92) and 10.459 mg (95% CI, 10.12-10.87) 
respectively. The potency ratio between spinal ropivacaine and bupivacaine was 0.89. Conclusion: Ropivacaine 
provided clinically surgical anaesthesia of shorter duration without compromising neonatal outcome and can be used 
as a safe alternative to bupivacaine.
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INTRODUCTION:
 Spinal anesthesia is considered a reasonable 
option for cesarean section. Intrathecal drugs like 
bupivacaine and ropivacaine have been used either 
alone or in combination with various opioids. 
Ropivacaine, a pure s-(-) enantiomer aminoamide 
long acting local anesthetic agent with structural 
and pharmacological similarity to bupivacaine.[1] 
At high doses, it produces surgical anesthesia and 
at lower doses it produces analgesia (sensory block) 
with limited and non-progressive motor block. As 
compared to bupivacaine, the motor block is often 
slower in onset, shorter in duration and less potent.
 In-vitro, ropivacaine has shown less 
cardiotoxicity than the equivalent concentration of 
racemic bupivacaine. It has been registered for use 
in intrathecal spinal anesthesia. [3, 4] A number of 
studies have evaluated intrathecal use of ropivacaine 
for obstetric and non-obstetric patients.[5,6,7,8] 
There is, however, a lack of comparative studies and 
adequate information on the analgesic and anesthetic 
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potency of intrathecal ropivacaine and bupivacaine 
administration, especially in obstetric practice. This 
comparative study applies a model to determine 
the median effective dose (ED50) of intrathecal 
ropivacaine and bupivacaine for cesarean section 
and defines this as the Minimum Local Anesthetic 
Dose (MLAD).
METHODS:
 This is a comparative, up-down sequential 
allocation study conducted in the Department of 
Anesthesiology of a tertiary hospital over a period of 
six months from October, 2017 to March, 2018. The 
ethical approval was taken from Institutional Review 
Committee (KUSMS/IRC 93/17) Kathmandu 
University School of Medical Sciences. Written 
informed consent was obtained from all participants 
of the study.
 Sample size calculation was done using the 
formula, N = [ (Z1-α/2+Z1-β) / ES ]2where ES = 
(µ1- µ2) /σ. Assuming estimated standard deviation 
(σ) = 0.55, clinically important difference (µ1- µ2) = 
0.5 and taking α = 0.05 with desired power (1-β) of 
0.80, the minimum sample size was calculated to be 
19.34, that is 20 in each group.
 A total of 40 women scheduled for elective 
cesarean delivery at more than 37 weeks of gestation 
and ASA physical status class I or II were enrolled 
into the study. Indications for cesarean section 
included previous cesarean section, transverse lie, 
complete placenta previa, pregnancy with tumors in 
lower uterine segment and primi breech presentation. 
All the participants were pre-medicated with 150 mg 
of ranitidine two hours before surgery. They were 
not given opioids during the study period.
 They were divided randomly into two groups 
of twenty each, using a computer generated random 
numbers list. Intravenous access was obtained with 
an 18G cannula through which all participants were 
pre-loaded with a balanced crystalloid solution of 
one liter over ten minutes before inducing Combined 
Spinal Epidural (CSE). The participants were not 
aware of the group that they were in and the observer 
was also kept blinded for the study drug dose injected 
by the independent anesthesiologists giving CSE in 
the sitting position by two space CSE technique at 
the L3-L4 interspace.[9,10] After confirming a free 
flow of cerebrospinal fluid(CSF), the study drug was 
injected at a rate of approximately 0.2ml/second 
intrathecally, to the allocated group accordingly 
by an anesthetist not related to the study. The dose 
of ropivacaine or bupivacaine in all syringes was 
taken by the response of the previous participant 
to a greater or lesser dose according to the vertical 
sequential allocation. The starting dose was 13mg 
for both ropivacaine and bupivacaine group. An 
anesthesia nurse who had no further role in the study 
prepared the syringes with the solution.
 Sensory level to pinpricks was assessed by 
the Hollmen scale: 0= ability to appreciate a pinprick 
as sharp; 1= ability to appreciate a pinprick as less 
sharp; 2= inability to appreciate a pin prick as sharp 
(analgesia); 3= inability to appreciate a pin prick 
as pin touching (analgesia). The participants were 
assessed before cesarean delivery, at skin incision, 
uterine incision, birth, peritoneal closure and at 
the end of the surgery. There were three possible 
outcomes. a) Effective: Women declared a Visual 
Analogue Pain Scale (VAPS)≤ 30mm and did not 
require an epidural rescue bolus; this result directed 
a decrease of 0.3mg in the dose of bupivacaine or 
ropivacaine for the next participant in the same 
group, b) Ineffective: Women reported a VAPS 
30mm which resulted in the administration of 10 ml 
epidural 2% lidocaine. A bupivacaine or ropivacaine 
0.3mg increment was directed for the next patient 
in the same group. c) Rejected: Women reported a 
VAPS 30mm which failed to rescue bolus or some 
problems with CSE occurred. This result directed a 
repeat of the same dose of the same drug in the same 
group.
 The intra operative monitors used were heart 
rate (HR), electrocardiogram (ECG), non-invasive 
blood pressure (NIBP) and oxygen saturation 
(SpO2). A consultant anesthesiologist on duty on the 
day of study period recorded these parameters before 
intrathecal injection and at three minutes interval 
until delivery, then every five minutes through 
surgery. Maternal hypotension was defined as a 20% 
reduction in systolic arterial pressure from baseline 
values and was treated promptly with intravenous 
ephedrine 10mg. During intra-operative period, the 
onset of action time in both the drugs was noted 
from incision up to closure of skin and postoperative 
complications like hypotension, nausea and vomiting 
were noted.
 The data collection was done mainly 
using the questionnaire which was filled up by the 
anesthesiologists regarding level of block, pain score 
using visual analogue scale, duration of anesthesia, 
hypotensive effect and post-operative nausea and 
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vomiting. Patient and obstetrics data were tabulated 
into Microsoft Excel and analyzed with the Statistical 
Package for Social Sciences (SPSS™) version 21. It 
was presented as mean (+SD), Median (IQR) and 
was analyzed using analysis of variance and Chi-
square test respectively.
 The significance of difference between 
two groups was evaluated by student's t test. The 
significance level for all tests was set at p<0.05. The 
MLAD for both bupivacaine and ropivacaine was 
calculated with 95% confidence interval using the 
formula of Dixon and Massey.
RESULT:
 A total of 40 consecutive eligible participants, 
enrolled into the study, were randomized into 
two study groups. The groups were comparable 
in terms of patient characteristics (age, weight, 
duration of surgery, ASA grade, APGAR score and 
the gestational age), and baseline vital parameters. 
The anesthetic and surgical techniques were 
standardized for both groups. The new born babies 
had a mean APGAR score (±SD) of 9.0(±0.20) 
and 9.5(±0.35) at five minutes in the bupivacaine 
and ropivacaine groups respectively (Table 1). 
 The intrathecal MLAD (95% CI) of 
ropivacaine was 11.6mg (11.2-12.6mg) and that 
of bupivacaine was 11.25mg (10.0-12.5mg), 
using the formula of Dixon and Massey (Figures 
1 and 2). The relative potency ratio between 
spinal ropivacaine and bupivacaine was 0.90. 
 Anesthesia was successfully performed 
within the predetermined criteria in all 20 
patients in both groups. The participants labelled 
‘ineffective' were pain free at skin incision or at 
delivery, but required supplementary analgesia 
at peritoneal closure. All patients who required 
epidural top-ups obtained good pain relief. 
 The mean MAP decreased significantly in 
both the groups compared to baseline/pre-operative 
values (p<0.005). The percentage of participants 
with hypotension was 36.5% in the ropivacaine 
and 60% in the bupivacaine group. The results 
were statistically significant both with p=0.032. 
 Bradycardia occurred during intra-operative 
period in two patients in each group. There were no 
significant differences between the two groups with 
respect to respiratory rate and oxygen saturation. 
Eight participants in bupivacaine group and six in 
ropivacaine group required ephedrine for correction 
of hypotension. Three participants in ropivacaine 
and five in bupivacaine group required ondansetron 
Table 1. Comparison of demographic profile, clinical characteristics and neonatal outcome between the study groups (N=40)
Variables 
Ropivacaine group 
(n=20)
Bupivacaine group 
(n=20)
P-value
Age in years, mean +SD 26.7±5.3 25.4±4.7 >0.05
Weight in kg, mean + SD 58.2±7.2 60.3±8.3 >0.05
Height in cm, mean + SD 153±6.5 152±5.5 >0.05
ASA grade (I/II) 16/4 17/3 >0.05
Duration of surgery in minutes, mean + SD 52±7.0 56±6.0 >0.05
APGAR Score at 5 minutes, mean + SD 9±0.20 9.5±0.35 >0.05
Gestational age in weeks, mean + SD 37.2±1.4 37.8±1.8 >0.05
Figure 1. The MLAD of bupivacaine for cesarean section was 
10.459 mg (CI 95%: 10.12–10.87)), using the formula of Dixon 
and Massey.
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for correction of vomiting. Incidence of hypotension, 
consumption of ephedrine and episodes of nausea 
and vomiting were similar between the groups. 
DISCUSSION:
 The MLAD model has been used in the 
investigation of analgesic requirements in labour.
[11] A relatively recent concept of minimum local 
anesthetic concentration determines the median 
effective dose and potencies of local anesthetics for 
spinal anesthesia.[12] A study by Stocks et al.[13] 
established the MLAD of intrathecal bupivacaine 
in parturients to determine the minimum local 
analgesic concentration of epidural local anesthetic. 
 In our study, we used the sequential allocation 
design for cesarean section to discover any difference 
in the estimation of the ED50 found in previous 
clinical studies with other statistical method. Khaw 
et al.[6], in his dose response study with plain spinal 
ropivacaine for cesarean delivery, determined the 
effective doses for ED50 to be 16.5 mg ( 95% CI, 14.1 
– 18.8) and ED95 to be 26.8 mg ( 95% CI, 23.6 – 34.1). 
 In another study done by Celleno et al. 
[14], the ED50 of plain ropivacaine for cesarean 
section was reported to be 14.22mg. This study 
showed a higher ED50 than ours. We attributed 
this difference to density of ropivacaine solutions 
administered intrathecally. The ropivacaine solution 
used in this study was isobaric where as that used 
in previous studies was hyperbaric. The feature 
of the neuraxial block during spinal anesthesia 
depends on the baricity, and the position of the 
patient. In parturients, while performing spinal 
anesthesia in lateral position the level of head is 
lower than the hip as the width of hips is usually 
larger than the shoulders in women. Further more, 
during pregnancy the gap is even higher. During the 
hyperbaric solution injection, in lateral position, the 
drug solution moves cephalad due to gravity. Unlike 
hyperbaric, isobaric solution is not affected by the 
gravity. In order to avoid the spread, this hyperbaric 
solution in our study was given in a sitting position. 
 In our study, we found the MLAD of 
bupivacaine was 11.25mg and ropivacaine was 
11.6mg. This finding was similar to the study done 
in Meerut by Singh S et al. where MLAD of 0.5% of 
hyperbaric bupivacaine was 12.5mg and for 0.75% 
isobaric ropivacaine, it was 24mg.[15] However in 
their study, they used 0.75% isobaric ropivacaine 
whereas, we used 0.5% isobaric ropivacaine. In a 
similar study done by Tadeusz et al. [16] in Poland 
and Fei Xiao et al. [17] in China, the MLADs of 
intrathecal ropivacaine and bupivacaine for cesarean 
delivery were reported 9.45mg and 7.33 respectively. 
These results are consistent with the present study with 
only difference that they performed spinal anesthesia 
in L2-3 space whereas we performed in L3-4 space. 
 In another study done in Peking University 
by Geng Zhi-yu et al.,[18] the intrathecal 
MLAD was 9.45mg (95% CI, 8.45-10.56mg) for 
ropivacaine and 7.53mg (95%CI, 7.00-8.10mg) 
for bupivacaine. This was slightly less than that 
found in our study. This difference can be attributed 
to the density of ropivacaine and bupivacaine. 
Likewise, a similar study done in Lucknow 
by Gupta A et al.[19] had found the MLAD of 
ropivacaine was 12.5mg in combination with 25mg 
of fentanyl which is consistent with our study. 
 Similar to our study, another study by 
Whiteside et al. comparing 15 mg of 0.5 % ropivacaine 
or 0.5 % bupivacaine in 8% glucose, reported that 
ropivacaine was reliable for spinal anaesthesia for 
lesser duration and with lesser hypotension than 
bupivacaine.[20] Another study by McNamee et 
al.[21] reported intrathecal administration of 17.5 
mg plain ropivacaine 0.5% or plain bupivacine 0.5% 
also had similar effective spinal anesthesia for total 
hip arthroplasty.[21]
CONCLUSION: 
Figure 2. The MLAD of ropivacaine for caesarean section was 
11.63mg  (95%CI, 11.5-12.92) using the formula of Dixon and 
Massey
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 For elective cesarean delivery under spinal 
anesthesia, 11.6 mg of 0.5% isobaric ropivacaine 
is an effective and safe alternative to bupivacaine. 
Ropivacaine provided clinically surgical anaesthesia 
of shorter duration without compromising neonatal 
outcome.
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